TEVA PHARMACEUTICAL INDUSTRIES LTD Form SC 13G/A February 09, 2009 CUSIP NO. 881624209

13G

Page 1 of 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Name of Issuer)

American Depository Shares (as evidenced by American Depository Receipts), each representing one Ordinary Share

(Title of Class of Securities)

8816242091

(CUSIP Number)

December 31, 2008 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

X Rule 13d-1(b)

- o Rule 13d-1(c)
- o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this

form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP N	O. 881624209	13G	Page 2 of 13
1.	NAMES OF REPORTING PERSONS.		
	Franklin Resources, Inc.		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GRO	OUP	
	(a) (b) X		
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5. SOLE VOTING POWER

(See Item 4)

6. SHARED VOTING POWER

(See Item 4)

7. SOLE DISPOSITIVE POWER

(See Item 4)

8. SHARED DISPOSITIVE POWER

(See Item 4)

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,379,5651

- 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0
- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.3%

12. TYPE OF REPORTING PERSON

HC, CO (See Item 4)

CUSIP NO	0. 881624209	13G	Page 3 of 13
1.	NAMES OF REPORTING PERSONS.		
	Charles B. Johnson		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GRO	DUP	
	(a) (b) X		
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	USA		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			

5. SOLE VOTING POWER

800 (See Item 4)

6. SHARED VOTING POWER

(See Item 4)

7. SOLE DISPOSITIVE POWER

800 (See Item 4)

8. SHARED DISPOSITIVE POWER

(See Item 4)

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,380,365

- 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0
- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.3%

12. TYPE OF REPORTING PERSON

HC, IN (See Item 4)

CUSIP NO. 881624209 13G Page 4 of 13 NAMES OF REPORTING PERSONS. 1. Rupert H. Johnson, Jr. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) Х 3. SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION 4. USA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5. SOLE VOTING POWER

(See Item 4)

6. SHARED VOTING POWER

(See Item 4)

7. SOLE DISPOSITIVE POWER

(See Item 4)

8. SHARED DISPOSITIVE POWER

(See Item 4)

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,379,565

- 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.3%

12. TYPE OF REPORTING PERSON

HC, IN (See Item 4)

(CUSIP NO	0. 881624209	13G	Page 5 of 13
:	Item 1.			
	(a)	Name of Issuer		
		TEVA PHARMACEUTICAL INDUSTRIES LIMITED		
	(b)	Address of Issuer's Principal Executive Offices		
5 Basel Street				
P.O. Box 3190				
Petach Tikva 49131, Israel				

Item 2.

(a)	Name of Person Filing		
	(i):	Franklin Resources, Inc.	
	(ii):	Charles B. Johnson	
	(iii):	Rupert H. Johnson, Jr.	

(b) Address of Principal Business Office or, if none, Residence

One Franklin Parkway San Mateo, CA 94403-1906

(c) Citizenship

(i): Delaware

(ii) and (iii): USA

(d) Title of Class of Securities

Depository Shares (as evidenced by American Depository Receipts), each representing one Ordinary Share

(e) CUSIP Number

881624209

CUSIP NO.	881624209	13G	

Page 6 of 13

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 - (g)

BAK BRKM3 BRKM5 BRKM6 XBRK	13.87 12.10 12.78 10.70 4.97	14.38 12.48 13.10 10.74 5.22	14.96 12.80 13.48 10.77 5.44
Mar/10			
BAK	14.33	14.73	15.34
BRKM3	11.70	12.13	12.40
BRKM5	12.65	13.04	13.40
BRKM6	10.75	10.75	10.75
XBRK	5.31	5.49	5.70
Apr/10			
BAK	13.71	14.43	15.04
BRKM3	10.95	11.38	11.79
BRKM5	12.31	12.74	13.17
BRKM6	10.75	10.75	10.75
XBRK	4.93	5.39	5.63

iv. Average quotation for the last ninety (90) days

Tickers Braskem last 90 days ∏ 03/03/10 to 05/31/10	Minimum	Average	Maximum
BAK	10.98	13,94	15.34
BRKM3	8.60	11.08	12.30
BRKM5	10.11	12.36	13.40
BRKM6	10.00	10.66	10.75
XBRK	4.20	5.29	5.70

Note: BAK (US\$/share), XBRK (/share), BRKM (R\$/share)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 04, 2010

BRASKEM S.A.

By:

/s/ Marcela Aparecida Drehmer Andrade

Name: Title: Marcela Aparecida Drehmer Andrade Chief Financial Officer

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. These statements are statements that are not historical facts, and are based on management's current view and estimates offuture economic circumstances, industry conditions, company performance and financial results. The words "anticipates", "believes", "estimates", "expects", "plans" and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.